The FDA has approved tadalafil (Cialis) for the once daily use as a treatment for benign prostatic hyperplasia (BPH). The agency also approved the medication for once daily use as a treatment for men ...

HSHS St. Elizabeth’s Hospital is proud to announce the 100th Aquablation therapy procedure, marking a significant milestone ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

Therapeutic Dr Allen's Devices are designed to treat different chronic health conditions, including kidney stones (known as nephrolithiasis), prostate enlargement (commonly known as BPH), chronic ...

A regulatory decision is expected in the third quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for vibegron for the treatment of men ...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Zenflow, Inc. announced today the U.S. Food and Drug Administration (FDA) approval of the Zenflow Spring(R) Implant and Delivery System ...

Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Drug therapy for BPH can be categorized into two groups: agents that interfere with testosterone's stimulatory effect on prostate enlargement and agents that relax prostatic smooth muscle. Of the ...

NEW BERN, N.C. (WNCT) — The Urology team at CarolinaEast Health System announced they are offering A quablation therapy and have completed their 100th treatment. A quablation therapy treats the lower ...